Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.41 |
| ▸ | MEN1 | O00255 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | LMNA | P02545 | 5/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.41 |
| ▸ | GLA | P06280 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.41 |
| ▸ | BLM | P54132 | 2/20 | 0.41 |
| ▸ | RGS12 | O14924 | 1/20 | 0.41 |
| ▸ | GMNN | O75496 | 1/20 | 0.41 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | PRKCG | P05129 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL307690 | 0.70 | TYMS (0.39) | — | |
| SCHEMBL9194801 | 0.70 | PARP1 (0.46) | MEN1KMT2AALDH1A1LMNAKDM4E | |
| SCHEMBL4230483 | 0.70 | CDK5 (0.49) | KMT2AKDM4EHSD17B10 | |
| SCHEMBL215326 | 0.70 | PARP1 (0.46) | MAPTMEN1KMT2AALDH1A1TDP1 | |
| Hydrochloric Acid SCHEMBL5496370 | 0.69 | PARP1 (0.45) | MAPTMEN1KMT2AALDH1A1TDP1 | |
| SCHEMBL2962689 | 0.69 | MEN1 (0.43) | MAPTMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL2612577 | 0.66 | MAPT (0.56) | MAPTMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL68635 | 0.66 | NPC1 (0.55) | MAPTMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL13363917 | 0.66 | MAPT (0.61) | MAPTMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL29824315 | 0.65 | CA12 (0.42) | MEN1KMT2ATSHRCDC25BCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9598418-B2 | Substituted phthalazin-1 (2H)-one derivatives as selective inhibitors of poly (ADP-ribose) polymerase-1 | CADILA HEALTHCARE LIMITED (IN) | 2017-03-21 | — | — | US | disclosed |
| EP-2938598-B1 | SUBSTITUTED PHTHALAZIN-1(2H)-ONE DERIVATIVES AS SELECTIVE INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE-1 | CADILA HEALTHCARE LTD (IN) | 2016-12-21 | — | — | EP | disclosed |
| EP-2938598-A1 | SUBSTITUTED PHTHALAZIN-1 (2H)-ONE DERIVATIVES AS SELECTIVE INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE-1 | Cadila Healthcare Limited (IN) | 2015-11-04 | — | — | EP | disclosed |
| US-20150291603-A1 | SUBSTITUTED PHTHALAZIN-1 (2H)-ONE DERIVATIVES AS SELECTIVE INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE-1 | CADILA HEALTHCARE LIMITED (IN) | 2015-10-15 | — | — | US | disclosed |
| US-20150141580-A1 | OPTIMIZED DRUG CONJUGATES | SYNDEVRX, INC. | 2015-05-21 | — | — | US | disclosed |
| WO-2014102817-A1 | SUBSTITUTED PHTHALAZIN-1 (2H)-ONE DERIVATIVES AS SELECTIVE INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE-1 | CADILA HEALTHCARE LIMITED (IN) | 2014-07-03 | — | — | WO | disclosed |
| US-20130137831-A1 | OPTIMIZED DRUG CONJUGATES | SYNDEVRX, INC. | 2013-05-30 | — | — | US | disclosed |
| EP-2575887-A1 | OPTIMIZED DRUG CONJUGATES | Syndevrx (US) | 2013-04-10 | — | — | EP | disclosed |
| US-20110294952-A1 | Optimized Drug Conjugates | SynDevRX (US) | 2011-12-01 | — | — | US | disclosed |
| WO-2011150088-A1 | OPTIMIZED DRUG CONJUGATES | SynDevRX (US) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294952-A1 | Optimized Drug Conjugates | ABCB1, ABCG2, UGT1A3 | MAPT 793/4885MEN1 1471/4885KMT2A 2109/4885 |
| US-20150141580-A1 | OPTIMIZED DRUG CONJUGATES | ABCB1, ABCG2, UGT1A3 | MAPT 793/4885MEN1 1471/4885KMT2A 2109/4885 |
| US-20150291603-A1 | SUBSTITUTED PHTHALAZIN-1 (2H)-ONE DERIVATIVES AS SELECTIVE INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE-1 | PARP1, PARP11, PARP2 | MAPT 55/4885MEN1 2986/4885KMT2A 1999/4885 |
| US-20130137831-A1 | OPTIMIZED DRUG CONJUGATES | ABCB1, ABCG2, UGT1A3 | MAPT 793/4885MEN1 1471/4885KMT2A 2109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.